Sofinnova Investments’s BioAtla BCAB Stock Holding History

Sofinnova Investments’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-60	Closed	-$102K	–	68
2020 Q4	$102K	Buy	+60	New	+$100K	0.01%	68

Other funds holding BCAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Sofinnova Investments's BCAB Position: Q1 2021 in Review

Sofinnova Investments sold out of BioAtla (BCAB) in Q1 2021, closing a stake of 60 shares — an estimated $102K sold.

Sofinnova Investments first reported a position in BCAB in Q4 2020 and held it in 1 quarter. The position peaked at $102K in Q4 2020. 62 funds tracked by Wall St. Rank hold BCAB as of Q1 2021.

Sofinnova Investments reported no remaining BioAtla position as of Q1 2021 after selling out during the quarter.
Sofinnova Investments sold 60 BioAtla shares in Q1 2021, an estimated $102K.
Sofinnova Investments first reported a position in BioAtla in Q4 2020 and held it in 1 quarter.
Sofinnova Investments's BioAtla position peaked at $102K in Q4 2020.
62 funds tracked by Wall St. Rank held BioAtla as of Q1 2021.

Based on Sofinnova Investments's 13F filing for Q1 2021, filed 14 May 2021.